-
Something wrong with this record ?
In Vitro Interaction of Binuclear Copper Complexes with Liver Drug-Metabolizing Cytochromes P450
A. Špičáková, Z. Horáčková, P. Kopel, P. Anzenbacher
Status not-indexed Language English Country Switzerland
Document type Journal Article
Grant support
IGA_LF_2024_006 and IGA_PrF_2024_013
Internal Grants of Palacký University
NLK
Directory of Open Access Journals
from 2009
Free Medical Journals
from 2009
PubMed Central
from 2004
Europe PubMed Central
from 2004
ProQuest Central
from 2004-01-01
Open Access Digital Library
from 2004-01-01
Open Access Digital Library
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2004
PubMed
39338356
DOI
10.3390/ph17091194
Knihovny.cz E-resources
- Publication type
- Journal Article MeSH
Two copper(II) mixed ligand complexes with dicarboxylate bridges were prepared and studied, namely [Cu2(μ-fu)(pmdien)2(H2O)2](ClO4)2 (complex No. 5) and [Cu2(μ-dtdp)(pmdien)2(H2O)2](ClO4)2 (complex No. 6), where H2fu = fumaric acid, pmdien = N,N,N',N′′,N′′ pentamethyldiethylenetriamine, and H2dtdp = 3,3'-dithiodipropionic acid. The copper atoms are coordinated in the same mode by the tridentate pmdien ligand and oxygen of water molecules, and they only differ in the dicarboxylate bridge. This work is focused on the study of the inhibitory effect of these potential antimicrobial drugs on the activity of the most important human liver drug-metabolizing enzymes, cytochromes P450 (CYP), especially their forms CYP2C8, CYP2C19, and CYP3A4. The obtained results allow us to estimate the probability of potential drug interactions with simultaneously administrated drugs that are metabolized by these CYP enzymes. In conclusion, the presence of adverse effects due to drug-drug interactions with concomitantly used drugs cannot be excluded, and hence, topical application may be recommended as a relatively safe approach.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24017843
- 003
- CZ-PrNML
- 005
- 20241016081949.0
- 007
- ta
- 008
- 241008s2024 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ph17091194 $2 doi
- 035 __
- $a (PubMed)39338356
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Špičáková, Alena $u Department of Pharmacology, Faculty of Medicine, Palacký University Olomouc, Hněvotínská 3, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000302391300 $7 xx0245951
- 245 10
- $a In Vitro Interaction of Binuclear Copper Complexes with Liver Drug-Metabolizing Cytochromes P450 / $c A. Špičáková, Z. Horáčková, P. Kopel, P. Anzenbacher
- 520 9_
- $a Two copper(II) mixed ligand complexes with dicarboxylate bridges were prepared and studied, namely [Cu2(μ-fu)(pmdien)2(H2O)2](ClO4)2 (complex No. 5) and [Cu2(μ-dtdp)(pmdien)2(H2O)2](ClO4)2 (complex No. 6), where H2fu = fumaric acid, pmdien = N,N,N',N′′,N′′ pentamethyldiethylenetriamine, and H2dtdp = 3,3'-dithiodipropionic acid. The copper atoms are coordinated in the same mode by the tridentate pmdien ligand and oxygen of water molecules, and they only differ in the dicarboxylate bridge. This work is focused on the study of the inhibitory effect of these potential antimicrobial drugs on the activity of the most important human liver drug-metabolizing enzymes, cytochromes P450 (CYP), especially their forms CYP2C8, CYP2C19, and CYP3A4. The obtained results allow us to estimate the probability of potential drug interactions with simultaneously administrated drugs that are metabolized by these CYP enzymes. In conclusion, the presence of adverse effects due to drug-drug interactions with concomitantly used drugs cannot be excluded, and hence, topical application may be recommended as a relatively safe approach.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Horáčková, Zuzana $u Laboratory of Growth Regulators, Faculty of Science, Palacký University & Institute of Experimental Botany of the Czech Academy of Sciences, Šlechtitelů 27, 78 371 Olomouc, Czech Republic
- 700 1_
- $a Kopel, Pavel $u Department of Inorganic Chemistry, Faculty of Science, Palacký University Olomouc, 17. Listopadu 1192/12, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000342169544 $7 mzk2005300913
- 700 1_
- $a Anzenbacher, Pavel $u Department of Pharmacology, Faculty of Medicine, Palacký University Olomouc, Hněvotínská 3, 779 00 Olomouc, Czech Republic $1 https://orcid.org/000000015904337X $7 xx0034447
- 773 0_
- $w MED00184066 $t Pharmaceuticals $x 1424-8247 $g Roč. 17, č. 9 (2024)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39338356 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241008 $b ABA008
- 991 __
- $a 20241016081944 $b ABA008
- 999 __
- $a ok $b bmc $g 2196384 $s 1229794
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 17 $c 9 $e 20240910 $i 1424-8247 $m Pharmaceuticals $n Pharmaceuticals (Basel) $x MED00184066
- GRA __
- $a IGA_LF_2024_006 and IGA_PrF_2024_013 $p Internal Grants of Palacký University
- LZP __
- $a Pubmed-20241008